Current Limitations of CAR T-Cell Therapy in Multiple Myeloma: Muhamed Baljevic, MD

Video

The assistant professor from University of Nebraska Medical Center discussed the current limitations of CAR T-cell therapy in multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Muhamed Baljevic, MD, assistant professor, Department of Internal Medicine, Division of Oncology and Hematology, College of Medicine, University of Nebraska Medical Center, to learn more about the current limitations of CAR T-cell therapy in multiple myeloma.

Baljevic discussed clinical trials evaluating CAR T-cell therapy in multiple myeloma in which some patients who underwent apheresis and CAR T-cell collection were unable to receive the treatment because their disease was too aggressive and dynamic. Even with bridging therapy, these patients were unable to wait the 4 to 5 weeks required to generate the CAR T-cell therapy.

Additionally, a significantly number of patients were not referred for CAR T-cell therapy because they lived too far away from an academic center that offers the treatment, Baljevic explains. These patients, as well as older patients and those with poor performance statuses, represent a population with unmet need for CAR T-cell therapy in multiple myeloma.

However, emerging constructs that have been optimized to be potentially safer and more effective could have clinical utility in these patient populations, Baljevic concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.